Catabasis Pharmaceuticals Profile

USD 0.01399  1.69%

Acquisition by Jean George of 6500 shares of Catabasis Pharmaceuticals subject to Rule 16b-3

Catabasis Pharmaceuticals insider trading alert for grant of stock option (right to buy) by Jean George, the corporate stakeholder, on September 19, 2018. This event was filed by Catabasis Pharmaceuticals with SEC on 2016-08-05. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Catabasis Pharmaceuticals Summary

Catabasis Pharmaceuticals (CATB) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 36 people. Catabasis Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Micro-Cap' category with current market capitalization of 59.96 M. Catabasis Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. This company has 71.04 M outstanding shares of which 158.42 K shares are currently shorted by private and institutional investors with about 0.18 trading days to cover. N/A currently holds about 49.93 M in cash with (25.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7.
Check Catabasis Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Catabasis Pharmaceuticals Target Price Odds Analysis

Odds Below 0.844HorizonTargetOdds Above 0.844
96.44%30 days 0.84 3.52%
Based on normal probability distribution, the odds of Catabasis Pharmaceuticals to move above current price in 30 days from now is under 4% (This Catabasis Pharmaceuticals probability density function shows the probability of Catabasis Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Catabasis Pharmaceuticals Top Holders

Catabasis Pharmaceuticals Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Federated Investors IncCommon Shares10.4 M10 M
Sv Health Investors LlcCommon Shares2.9 M2.7 M
Alyeska Investment Group LpCall Options1000 K959 K
View Catabasis Pharmaceuticals Diagnostics

Catabasis Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Catabasis Pharmaceuticals Key Fundamentals

Catabasis Pharmaceuticals Against Markets

Catabasis Pharmaceuticals Current Ratings

Catabasis Pharmaceuticals 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Catabasis Pharmaceuticals are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company was founded in 2008 and is based in Cambridge, Massachusetts. Catabasis Pharmaceuticals operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 36 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Catabasis Pharmaceuticals SEC Filings
Catabasis Pharmaceuticals SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameCatabasis Pharmaceuticals
CEOJill MilneView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Biotechnology
InstrumentUSA Stock View All
Business AddressBuilding 1400E
ExchangeBATS Exchange
Phone617 349 1971
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestAugust 31, 2018

Catabasis Pharmaceuticals Directors

Catabasis Pharmaceuticals Corporate Directors

Jean George Director
Michael Kishbauch Director
Burt Adelman Director
Check also Trending Equities. Please also try Price Transformation module to use price transformation models to analyze depth of different equity instruments across global markets.